

High Residual Platelet Reactivity After Clopidogrel Load Events Among Patients With Acute Coronary Syndrome

JAMA - Journal of the American Medical Association

306, 1215

DOI: [10.1001/jama.2011.1332](https://doi.org/10.1001/jama.2011.1332)

Citation Report

#	ARTICLE	IF	CITATIONS
1	High Residual Platelet Reactivity and Thrombotic Events. JAMA - Journal of the American Medical Association, 2011, 306, 2561-2561.	3.8	1
2	Dosing Clopidogrel Based on CYP2C19 Genotype and the Effect on Platelet Reactivity in Patients With Stable Cardiovascular Disease. JAMA - Journal of the American Medical Association, 2011, 306, 2221-8.	3.8	313
3	Applying Platelet Function Testing in Clinical Practice. JAMA - Journal of the American Medical Association, 2011, 306, 1260.	3.8	9
4	Advances in the monitoring of anti-P2Y ₁₂ therapy. Platelets, 2012, 23, 510-525.	1.1	22
5	The Role of Platelet Reactivity and Genotype Testing in the Prevention of Atherothrombotic Cardiovascular Events Remains Unproven. Circulation, 2012, 125, 1288-1303.	1.6	51
6	Treatment algorithm in patients with NSTEMI and unstable angina. , 2012, , 331-346.		0
7	Measured Drug Effect and Cardiovascular Outcomes in Patients Receiving Platelet P2Y ₁₂ Receptor Antagonists. JAMA - Journal of the American Medical Association, 2012, 308, 1806.	3.8	7
8	Current status of clopidogrel pharmacogenomics. Pharmacogenomics, 2012, 13, 1671-1674.	0.6	8
9	Platelet Function Testing in Atherothrombotic Disease. Current Pharmaceutical Design, 2012, 18, 5379-5391.	0.9	35
10	Interindividual Variability in the Efficacy of Oral Antiplatelet Drugs: Definitions, Mechanisms and Clinical Importance. Current Pharmaceutical Design, 2012, 18, 5344-5361.	0.9	59
11	Pharmacogenetics of Clopidogrel. Current Pharmaceutical Design, 2012, 18, 5309-5327.	0.9	16
12	Warfarin doses for anticoagulation therapy in elderly patients with chronic atrial fibrillation. Clinics, 2012, 67, 543-546.	0.6	11
13	Standard- vs High-Dose Clopidogrel Based on Platelet Function Testing After Percutaneous Coronary Intervention: The GRAVITAS Randomized Trial. Yearbook of Critical Care Medicine, 2012, 2012, 36-39.	0.2	0
14	Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial. Lancet, The, 2012, 379, 1705-1711.	6.3	341
15	Relationship between post-treatment platelet reactivity and ischemic and bleeding events at 1-year follow-up in patients receiving prasugrel. Journal of Thrombosis and Haemostasis, 2012, 10, 1999-2005.	1.9	112
16	2012 Update to The Society of Thoracic Surgeons Guideline on Use of Antiplatelet Drugs in Patients Having Cardiac and Noncardiac Operations. Annals of Thoracic Surgery, 2012, 94, 1761-1781.	0.7	256
17	Antiplatelets in acute coronary syndrome: personal perspectives. Expert Review of Cardiovascular Therapy, 2012, 10, 1487-1496.	0.6	8
18	Personalizing Antiplatelet Therapy With Clopidogrel. Clinical Pharmacology and Therapeutics, 2012, 92, 476-85.	2.3	12

#	ARTICLE	IF	CITATIONS
19	The Year in Non-ST-Segment Elevation Acute Coronary Syndrome. Journal of the American College of Cardiology, 2012, 60, 2127-2139.	1.2	13
20	Thrombosis and Acute coronary syndrome. Thrombosis Research, 2012, 129, 235-240.	0.8	77
22	Comparative Pharmacokinetics and Pharmacodynamics of Platelet Adenosine Diphosphate Receptor Antagonists and their Clinical Implications. Clinical Pharmacokinetics, 2012, 51, 429-442.	1.6	66
23	Inconsistencies surrounding the risk of adverse outcomes with concomitant use of clopidogrel and proton pump inhibitors. Expert Opinion on Drug Safety, 2012, 11, 275-284.	1.0	2
24	Stent thrombosis: an overview. Expert Review of Cardiovascular Therapy, 2012, 10, 599-615.	0.6	16
25	The Year in Interventional Cardiology. Journal of the American College of Cardiology, 2012, 59, 1497-1508.	1.2	6
26	Clinical Application of Cardiovascular Pharmacogenetics. Journal of the American College of Cardiology, 2012, 60, 9-20.	1.2	65
27	Ticagrelor Versus Prasugrel in Acute Coronary Syndrome Patients With High On-Clopidogrel Platelet Reactivity Following Percutaneous Coronary Intervention. Journal of the American College of Cardiology, 2012, 60, 193-199.	1.2	184
28	The Year in Atherothrombosis. Journal of the American College of Cardiology, 2012, 60, 932-942.	1.2	14
29	Personalized Cardiovascular Medicine: Status in 2012. Canadian Journal of Cardiology, 2012, 28, 693-699.	0.8	11
30	t-tests, non-parametric tests, and large studies—a paradox of statistical practice?. BMC Medical Research Methodology, 2012, 12, 78.	1.4	305
31	Stent Thrombosis: Incidence, Predictors and New Technologies. Thrombosis, 2012, 2012, 1-12.	1.4	53
32	Bleeding tendency in dual antiplatelet therapy with aspirin/clopidogrel: rescue of the template bleeding time in a single-center prospective study. Thrombosis Journal, 2012, 10, 3.	0.9	12
33	Late Stent Thrombosis: The Last Remaining Obstacle in Coronary Interventional Therapy. Current Cardiology Reports, 2012, 14, 408-417.	1.3	15
34	Residual Platelet Reactivity, Bleedings, and Adherence to Treatment in Patients Having Coronary Stent Implantation Treated With Prasugrel. American Journal of Cardiology, 2012, 109, 214-218.	0.7	66
35	Response variability to clopidogrel: is tailored treatment, based on laboratory testing, the right solution?. Journal of Thrombosis and Haemostasis, 2012, 10, 327-336.	1.9	54
36	Bioequivalence in the Real World Is a Complex Challenge. Journal of the American College of Cardiology, 2013, 61, 594-595.	1.2	14
37	Relation between the vasodilator-stimulated phosphoprotein phosphorylation assay and light transmittance aggregometry in East Asian patients after high-dose clopidogrel loading. American Heart Journal, 2013, 166, 95-103.	1.2	13

#	ARTICLE	IF	CITATIONS
38	ADP-Receptor Inhibitors in the Perioperative Period: The Good, the Bad, and the Ugly. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2013, 27, 779-795.	0.6	12
39	Rationale and Design of the On-Treatment Platelet Reactivity-Guided Therapy Modification FOR ST-Segment Elevation Myocardial Infarction (PLATFORM) Randomized Trial. <i>Journal of Interventional Cardiology</i> , 2013, 26, 221-227.	0.5	3
40	Platelet Function Testing and Tailored Antiplatelet Therapy. <i>Journal of Cardiovascular Translational Research</i> , 2013, 6, 316-328.	1.1	34
41	Platelet Function Testing in Patients with Acute Coronary Syndrome. <i>Journal of Cardiovascular Translational Research</i> , 2013, 6, 371-377.	1.1	6
42	Below-the-knee Interventions. <i>CardioVascular and Interventional Radiology</i> , 2013, 36, 302-311.	0.9	41
43	Platelet reactivity tests for assessing antiplatelet drug response: what the clinician needs to know. <i>Expert Review of Cardiovascular Therapy</i> , 2013, 11, 975-984.	0.6	4
44	Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study. <i>Lancet, The</i> , 2013, 382, 614-623.	6.3	740
45	Platelet Function Tests in Clinical Cardiology. <i>Journal of the American College of Cardiology</i> , 2013, 61, 2115-2129.	1.2	74
46	High post-clopidogrel platelet reactivity assessed by a point-of-care assay predicts long-term clinical outcomes in patients with ST-segment elevation myocardial infarction who underwent primary coronary stenting. <i>International Journal of Cardiology</i> , 2013, 167, 1877-1881.	0.8	28
47	Personalized antiplatelet therapy: The wrong approach?. <i>Archives of Cardiovascular Diseases</i> , 2013, 106, 481-486.	0.7	3
48	Routine Assessment of On-Clopidogrel Platelet Reactivity and Gene Polymorphisms in Predicting Clinical Outcome Following Drug-Eluting Stent Implantation in Patients With Stable Coronary Artery Disease. <i>JACC: Cardiovascular Interventions</i> , 2013, 6, 1166-1175.	1.1	49
49	Consensus and Update on the Definition of On-Treatment Platelet Reactivity to Adenosine Diphosphate Associated With Ischemia and Bleeding. <i>Journal of the American College of Cardiology</i> , 2013, 62, 2261-2273.	1.2	807
50	Incidence and Outcome of High On-Treatment Platelet Reactivity in Patients With Non-ST Elevation Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention (from the VIP). <i>Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 262 T</i> 792-798.	0.7	12
51	Clopidogrel pretreatment of patients with ST-elevation myocardial infarction does not affect platelet reactivity after subsequent prasugrel-loading: Platelet reactivity in an observational study. <i>Platelets</i> , 2013, 24, 549-553.	1.1	16
52	Increased platelet aggregation and turnover in the acute phase of ST-elevation myocardial infarction. <i>Platelets</i> , 2013, 24, 528-537.	1.1	27
53	Differential prognostic impact of high on-treatment platelet reactivity among patients with acute coronary syndromes versus stable coronary artery disease undergoing percutaneous coronary intervention. <i>American Heart Journal</i> , 2013, 165, 34-42.e1.	1.2	39
54	The impact of CYP2C19 genotype on cardiovascular events and platelet reactivity in patients with coronary artery disease receiving clopidogrel. <i>International Journal of Cardiology</i> , 2013, 168, 1594-1596.	0.8	14
55	Individualisation du traitement antiplaquettaire : quel est l'intérêt du monitoring plaquettaire ?. <i>Archives Des Maladies Du Coeur Et Des Vaisseaux - Pratique</i> , 2013, 2013, 35-41.	0.0	0

#	ARTICLE	IF	CITATIONS
56	Platelet Function and Genetic Testing. <i>Journal of the American College of Cardiology</i> , 2013, 62, S21-S31.	1.2	28
57	Platelet and leukocyte ROS production and lipoperoxidation are associated with high platelet reactivity in Non-ST elevation myocardial infarction (NSTEMI) patients on dual antiplatelet treatment. <i>Atherosclerosis</i> , 2013, 231, 392-400.	0.4	43
58	P2Y12 inhibitors adjunctive to primary PCI therapy in STEMI: Fighting against the activated platelets. <i>International Journal of Cardiology</i> , 2013, 163, 249-255.	0.8	15
59	Impact of high post-loading platelet aggregation on 30-day clinical outcomes after primary percutaneous coronary intervention. The antiplatelet regimen tailoring after primary PCI (ART-PCI) trial. <i>International Journal of Cardiology</i> , 2013, 167, 1632-1637.	0.8	7
60	Reply. <i>Journal of the American College of Cardiology</i> , 2013, 62, 1637.	1.2	0
61	Value of platelet pharmacogenetics in common clinical practice of patients with ST-segment elevation myocardial infarction. <i>International Journal of Cardiology</i> , 2013, 167, 2882-2888.	0.8	27
62	Platelet Inhibition by Abciximab Bolus-Only Administration and Oral ADP Receptor Antagonist Loading in Acute Coronary Syndrome Patients: The Blocking and Bridging Strategy. <i>Thrombosis Research</i> , 2013, 132, e36-e41.	0.8	19
63	Comparison of the Degree of Platelet Aggregation Inhibition With Prasugrel Versus Clopidogrel and Clinical Outcomes in Patients With Unprotected Left Main Disease Treated With Everolimus-Eluting Stents. <i>American Journal of Cardiology</i> , 2013, 112, 1843-1848.	0.7	7
64	Switching Acute Coronary Syndrome Patients From Prasugrel to Clopidogrel. <i>JACC: Cardiovascular Interventions</i> , 2013, 6, 158-165.	1.1	60
65	Platelet reactivity in the early and late phases of acute coronary syndromes according to cytochrome P450 2C19 phenotypes. <i>Journal of Cardiology</i> , 2013, 62, 158-164.	0.8	28
66	Elevated Plasma Fibrinogen Rather Than Residual Platelet Reactivity After Clopidogrel Pre-Treatment Is Associated With an Increased Ischemic Risk During Elective Percutaneous Coronary Intervention. <i>Journal of the American College of Cardiology</i> , 2013, 61, 23-34.	1.2	30
67	Clinical Tests of Platelet Function. , 2013, , 519-545.		9
68	ADP Receptor Antagonists. , 2013, , 1117-1138.		5
69	Prasugrel Monitoring and Bleeding in Real World Patients. <i>American Journal of Cardiology</i> , 2013, 111, 38-44.	0.7	41
70	We are 'shocked', 'frozen', and 'freed' by new data. <i>Nature Reviews Cardiology</i> , 2013, 10, 68-70.	6.1	1
71	Effects of clopidogrel on the platelet activation response in horses. <i>American Journal of Veterinary Research</i> , 2013, 74, 1212-1222.	0.3	22
72	Aspirin nonresponders in patients with ischaemic stroke. <i>Blood Coagulation and Fibrinolysis</i> , 2013, 24, 361-364.	0.5	3
73	Treatment Options for Patients With Poor Clopidogrel Response. <i>Cardiology in Review</i> , 2013, 21, 309-317.	0.6	10

#	ARTICLE	IF	CITATIONS
74	Potential clinical utility of genetic and platelet function tests in patients on treatment with clopidogrel. <i>Journal of Cardiovascular Medicine</i> , 2013, 14, S16-S21.	0.6	4
75	Clopidogrel, Prasugrel, or Ticagrelor? A Practical Guide to Use of Antiplatelet Agents in Patients With Acute Coronary Syndromes. <i>Postgraduate Medicine</i> , 2013, 125, 91-102.	0.9	41
76	Identifying responsiveness to oral P2Y12 receptor blockers. <i>Journal of Cardiovascular Medicine</i> , 2013, 14, S8-S15.	0.6	4
77	Effect on Platelet Reactivity From a Prasugrel Loading Dose After a Clopidogrel Loading Dose Compared With a Prasugrel Loading Dose Alone. <i>Circulation: Cardiovascular Interventions</i> , 2013, 6, 567-574.	1.4	42
78	Effects of Endothelial Dysfunction on Residual Platelet Aggregability After Dual Antiplatelet Therapy With Aspirin and Clopidogrel in Patients With Stable Coronary Artery Disease. <i>Circulation: Cardiovascular Interventions</i> , 2013, 6, 452-459.	1.4	21
79	Tailored Thienopyridine Therapy: No Urgency for CYP2C19 Genotyping. <i>Journal of the American Heart Association</i> , 2013, 2, e000131.	1.6	20
80	Advances in Our Understanding of "Resistance" to Antiplatelet Agents for Prevention of Ischemic Stroke. <i>Stroke Research and Treatment</i> , 2013, 2013, 1-7.	0.5	11
81	Recommendations for the standardization of light transmission aggregometry: a consensus of the working party from the platelet physiology subcommittee of SSC/ISTH. <i>Journal of Thrombosis and Haemostasis</i> , 2013, 11, 1183-1189.	1.9	398
82	Inhibition of platelet aggregation by prostaglandin E1 (PGE1) in diabetic patients during therapy with clopidogrel and aspirin. <i>Platelets</i> , 2013, 24, 145-150.	1.1	26
83	Comparison of platelet activity measurements by use of arterial and venous blood sampling. <i>Journal of Thrombosis and Haemostasis</i> , 2013, 11, 1922-1924.	1.9	13
84	Genetic Polymorphisms and Drug Interactions Leading to Clopidogrel Resistance: Why the Asian Population Requires Special Attention. <i>International Journal of Neuroscience</i> , 2013, 123, 143-154.	0.8	76
85	Reticulated platelets predict cardiovascular death in acute coronary syndrome patients. <i>Thrombosis and Haemostasis</i> , 2013, 109, 846-853.	1.8	119
86	Personalized antiplatelet therapy in acute coronary syndromes: a dead-end street or a future scenario?. <i>Interventional Cardiology</i> , 2013, 5, 601-604.	0.0	0
87	Identification of poor response to P2Y12 inhibitors in ACS patients with a new ELISA-based vasodilator-associated stimulated phosphoprotein (VASP) phosphorylation assay. <i>Thrombosis and Haemostasis</i> , 2013, 110, 1055-1064.	1.8	10
88	High on-treatment platelet reactivity " definition and measurement. <i>Thrombosis and Haemostasis</i> , 2013, 109, 792-798.	1.8	41
89	Interplay between Genetic and Clinical Variables Affecting Platelet Reactivity and Cardiac Adverse Events in Patients Undergoing Percutaneous Coronary Intervention. <i>PLoS ONE</i> , 2014, 9, e102701.	1.1	23
90	Randomized Comparison of the Platelet Inhibitory Efficacy between Low Dose Prasugrel and Standard Dose Clopidogrel in Patients Who Underwent Percutaneous Coronary Intervention. <i>Korean Circulation Journal</i> , 2014, 44, 82.	0.7	10
91	ANMCO/SICI-GISE paper on antiplatelet therapy in acute coronary syndrome. <i>European Heart Journal Supplements</i> , 2014, 16, C2-C28.	0.0	2

#	ARTICLE	IF	CITATIONS
92	Pharmacogenomics of Clopidogrel. , 2014, , 509-541.		1
93	Genotype- and phenotype-directed antiplatelet therapy selection in patients with acute coronary syndromes. <i>Expert Review of Cardiovascular Therapy</i> , 2014, 12, 1289-1303.	0.6	4
94	The Prognostic Impact of High On-Treatment Platelet Reactivity with Aspirin or ADP Receptor Antagonists: Systematic Review and Meta-Analysis. <i>BioMed Research International</i> , 2014, 2014, 1-13.	0.9	16
95	Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention. <i>European Heart Journal</i> , 2014, 35, 209-215.	1.0	224
96	The impact of smoking on clinical efficacy and pharmacodynamic effects of clopidogrel: a systematic review and meta-analysis. <i>Heart</i> , 2014, 100, 192-199.	1.2	21
97	Switching Patients from Clopidogrel to Prasugrel in Acute Coronary Syndrome: Impact of the Clopidogrel Loading Dose on Platelet Reactivity. <i>Journal of Interventional Cardiology</i> , 2014, 27, 365-372.	0.5	10
98	Pretreatment with P2Y ₁₂ Inhibitors in Non-“ST-Segment” Elevation Acute Coronary Syndrome: An Outdated and Harmful Strategy. <i>Circulation</i> , 2014, 130, 1904-1914.	1.6	36
99	Administration of a Loading Dose Has No Additive Effect on Platelet Aggregation During the Switch From Ongoing Clopidogrel Treatment to Ticagrelor in Patients With Acute Coronary Syndrome. <i>Circulation: Cardiovascular Interventions</i> , 2014, 7, 104-112.	1.4	29
100	The role of clinical parameters and of CYP2C19 G681 and CYP4F2 G1347A polymorphisms on platelet reactivity during dual antiplatelet therapy. <i>Blood Coagulation and Fibrinolysis</i> , 2014, 25, 369-374.	0.5	14
101	Protective Effects of Novel Metal-Nonoates on the Cellular Components of the Vascular System. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2014, 351, 500-509.	1.3	20
102	Prasugrel and ticagrelor. <i>Journal of Cardiovascular Medicine</i> , 2014, 15, 8-18.	0.6	4
103	Prognostic Role of Platelet Reactivity in Patients With Acute Coronary Syndromes. <i>Cardiology in Review</i> , 2014, 22, 313-318.	0.6	6
104	Single antiplatelet therapy after percutaneous coronary intervention in patients allergic to aspirin. <i>Cardiovascular Revascularization Medicine</i> , 2014, 15, 308-310.	0.3	5
105	Risk of Stroke in Patients With High On-Clopidogrel Platelet Reactivity to Adenosine Diphosphate After Percutaneous Coronary Intervention. <i>American Journal of Cardiology</i> , 2014, 113, 1807-1814.	0.7	5
106	Isn't It About Time We Learned How to Use Blood Transfusion in Patients With Ischemic Heart Disease?. <i>Journal of the American College of Cardiology</i> , 2014, 63, 1297-1299.	1.2	8
107	Pharmacodynamic Effects During the Transition Between Cangrelor and Ticagrelor. <i>JACC: Cardiovascular Interventions</i> , 2014, 7, 435-442.	1.1	68
108	Gender and Anti-thrombotic Therapy: from Biology to Clinical Implications. <i>Journal of Cardiovascular Translational Research</i> , 2014, 7, 72-81.	1.1	9
109	Optimizing P2Y ₁₂ Receptor Inhibition in Patients With Acute Coronary Syndrome on the Basis of Platelet Function Testing. <i>Journal of the American College of Cardiology</i> , 2014, 63, 1061-1070.	1.2	81

#	ARTICLE	IF	CITATIONS
110	Relationship between changes in platelet reactivity and ischemic events following percutaneous coronary intervention: A meta-regression analysis of 30 randomized trials. <i>Atherosclerosis</i> , 2014, 234, 176-184.	0.4	16
111	The use of platelet function testing in PCI and CABG patients. <i>Blood Reviews</i> , 2014, 28, 109-121.	2.8	17
112	Long-term clinical efficacy and safety of adding cilostazol to dual antiplatelet therapy for patients undergoing PCI: a meta-analysis of randomized trials with adjusted indirect comparisons. <i>Current Medical Research and Opinion</i> , 2014, 30, 37-49.	0.9	19
113	Global platelet hyperreactivity and elevated C-reactive protein levels predict long term mortality in STEMI patients. <i>Thrombosis Research</i> , 2014, 134, 884-888.	0.8	16
114	Switching from ticagrelor to prasugrel: A warning. <i>International Journal of Cardiology</i> , 2014, 176, 1089-1090.	0.8	2
115	The Path to Personalized Cardiovascular Medicine. , 2014, , 837-871.		0
116	2014 ESC/EACTS Guidelines on myocardial revascularization. <i>European Heart Journal</i> , 2014, 35, 2541-2619.	1.0	4,141
117	Prasugrel but not high dose clopidogrel overcomes the lansoprazole neutralizing effect of P2Y12 inhibition: Results of the randomized DOSAPI study. <i>European Journal of Clinical Pharmacology</i> , 2014, 70, 1049-1057.	0.8	9
118	Switching from clopidogrel to prasugrel in patients having coronary stent implantation. <i>Journal of Thrombosis and Thrombolysis</i> , 2014, 38, 395-401.	1.0	9
119	Serial clopidogrel dose adjustment after platelet function testing improves outcome of acute coronary syndrome patients undergoing percutaneous coronary intervention with high on-treatment platelet reactivity. <i>Journal of Thrombosis and Thrombolysis</i> , 2014, 38, 459-469.	1.0	18
120	Severe Left Ventricular Systolic Dysfunction is Independently Associated with High On-Clopidogrel Platelet Reactivity. <i>American Journal of Cardiovascular Drugs</i> , 2014, 14, 313-318.	1.0	4
121	Effectiveness of clopidogrel dose escalation to normalize active metabolite exposure and antiplatelet effects in CYP2C19 poor metabolizers. <i>Journal of Clinical Pharmacology</i> , 2014, 54, 865-873.	1.0	31
122	Residual platelet reactivity and outcomes with 5mg prasugrel therapy in elderly patients undergoing percutaneous coronary intervention. <i>International Journal of Cardiology</i> , 2014, 176, 874-877.	0.8	8
124	Reply. <i>American Journal of Cardiology</i> , 2014, 113, 2087.	0.7	1
125	Expert position paper on the management of antiplatelet therapy in patients undergoing coronary artery bypass graft surgery. <i>European Heart Journal</i> , 2014, 35, 1510-1514.	1.0	70
126	Platelet Function Testing in Contemporary Clinical and Interventional Practice. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2014, 16, 300.	0.4	34
127	Third generation P2Y12 antagonists inhibit platelet aggregation more effectively than clopidogrel in a myocardial infarction registry. <i>Thrombosis and Haemostasis</i> , 2014, 112, 266-272.	1.8	26
128	Cost-Effectiveness of Genotype-Guided and Dual Antiplatelet Therapies in Acute Coronary Syndrome. <i>Annals of Internal Medicine</i> , 2014, 160, 221-232.	2.0	84

#	ARTICLE	IF	CITATIONS
129	Cardiovascular Drugs and the Genetic Response. <i>Methodist DeBakey Cardiovascular Journal</i> , 2021, 10, 13.	0.5	8
130	Carboxylesterase 1-Mediated Drug-Drug Interactions between Clopidogrel and Simvastatin. <i>Biological and Pharmaceutical Bulletin</i> , 2015, 38, 292-297.	0.6	22
131	Ticagrelor overcomes high platelet reactivity in patients with acute myocardial infarction or coronary artery in-stent restenosis: a randomized controlled trial. <i>Scientific Reports</i> , 2015, 5, 13789.	1.6	19
132	Resistance to antiplatelet drugs. Can it be assessed?. <i>IJC Metabolic & Endocrine</i> , 2015, 8, 31-33.	0.5	2
133	No association between on-treatment platelet reactivity and bleeding events following percutaneous coronary intervention and antiplatelet therapy: A post hoc analysis. <i>Thrombosis Research</i> , 2015, 136, 947-954.	0.8	9
134	2015 ESC Guidelines for the Management of Acute Coronary Syndromes in Patients Presenting Without Persistent ST-segment Elevation. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2015, 68, 1125.	0.4	57
135	Platelet function testing in acute cardiac care – is there a role for prediction or prevention of stent thrombosis and bleeding?. <i>Thrombosis and Haemostasis</i> , 2015, 113, 221-230.	1.8	33
136	Prevalence and Impact of High Platelet Reactivity in Chronic Kidney Disease. <i>Circulation: Cardiovascular Interventions</i> , 2015, 8, e001683.	1.4	65
137	Influence of Genetic Polymorphisms on Clopidogrel Response and Clinical Outcomes in Patients with Acute Ischemic Stroke CYP2C19 Genotype on Clopidogrel Response. <i>CNS Neuroscience and Therapeutics</i> , 2015, 21, 692-697.	1.9	36
138	High maintenance dose of clopidogrel in patients with high on-treatment platelet reactivity after a percutaneous coronary intervention. <i>Coronary Artery Disease</i> , 2015, 26, 386-395.	0.3	4
139	CYP2C19 genotype plus platelet reactivity-guided antiplatelet therapy in acute coronary syndrome patients. <i>Pharmacogenetics and Genomics</i> , 2015, 25, 609-617.	0.7	14
140	Low On-Treatment Platelet Reactivity Predicts Long-Term Risk of Bleeding After Elective PCI. <i>Journal of Interventional Cardiology</i> , 2015, 28, 531-543.	0.5	3
141	Impact of Sex and Gender on the Efficacy of Antiplatelet Therapy: The Female Perspective. <i>Journal of Atherosclerosis and Thrombosis</i> , 2015, 22, 109-125.	0.9	16
142	Temporal variability in the antiplatelet effects of clopidogrel and aspirin after elective drug-eluting stent implantation. <i>Thrombosis and Haemostasis</i> , 2015, 114, 1020-1027.	1.8	14
143	Inflammatory and Antioxidant Pattern Unbalance in Clopidogrel-Resistant Patients during Acute Coronary Syndrome. <i>Mediators of Inflammation</i> , 2015, 2015, 1-12.	1.4	17
144	Comparing of Light Transmittance Aggregometry and Modified Thrombelastograph in Predicting Clinical Outcomes in Chinese Patients Undergoing Coronary Stenting with Clopidogrel. <i>Chinese Medical Journal</i> , 2015, 128, 774-779.	0.9	12
145	P2Y12 antagonists in non-ST-segment elevation acute coronary syndromes: latest evidence and optimal use. <i>Therapeutic Advances in Chronic Disease</i> , 2015, 6, 204-218.	1.1	4
146	Diagnosis and Evaluation of Stent Thrombosis with Optical Coherence Tomography. <i>Interventional Cardiology Clinics</i> , 2015, 4, 295-307.	0.2	0

#	ARTICLE	IF	CITATIONS
147	Platelet Function Testâ€“Guided Strategy. <i>Circulation: Cardiovascular Interventions</i> , 2015, 8, e002716.	1.4	1
148	Platelet Reactivity: Is There a Role to Switch?. <i>Progress in Cardiovascular Diseases</i> , 2015, 58, 278-284.	1.6	4
149	In-hospital switching between adenosine diphosphate receptor inhibitors in patients with acute myocardial infarction treated with percutaneous coronary intervention: Insights into contemporary practice from the TRANSLATE-ACS study. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2015, 4, 499-508.	0.4	68
150	Post receptor determinants of acute platelet response to clopidogrel in patients with symptomatic myocardial ischemia. <i>Vascular Pharmacology</i> , 2015, 65-66, 17-22.	1.0	6
151	Meta-Analysis Appraising High Maintenance Dose Clopidogrel in Patients Who Underwent Percutaneous Coronary Intervention With and Without High On-Clopidogrel Platelet Reactivity. <i>American Journal of Cardiology</i> , 2015, 115, 592-601.	0.7	8
152	Morphine Is Associated With a Delayed Activity of Oral Antiplatelet Agents in Patients With ST-Elevation Acute Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2015, 8, .	1.4	164
153	Residual platelet reactivity to predict long-term clinical outcomes after clopidogrel loading in patients with acute coronary syndromes: comparison of different cutoff values by light transmission aggregometry from the responsiveness to clopidogrel and stent thrombosis 2-acute coronary syndrome (RECLOSE 2-ACS) study. <i>Journal of Thrombosis and Thrombolysis</i> , 2015, 40, 76-82.	1.0	27
154	Stent thrombosis in a patient with high on-treatment platelet reactivity despite ticagrelor treatment. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2015, 4, 85-87.	0.4	20
155	Prognostic impact of high residual platelet reactivity after chronic total occlusion percutaneous coronary intervention in patients with diabetes mellitus. <i>International Journal of Cardiology</i> , 2015, 201, 561-567.	0.8	7
156	Large early variation of residual platelet reactivity in Acute Coronary Syndrome patients treated with clopidogrel. <i>Thrombosis Research</i> , 2015, 136, 335-340.	0.8	8
157	Optimal cutoff value of P2Y12 reaction units to prevent major adverse cardiovascular events in the acute periprocedural period: Post-hoc analysis of the randomized PRASFIT-ACS study. <i>International Journal of Cardiology</i> , 2015, 182, 541-548.	0.8	49
158	A time course study of high on treatment platelet reactivity in acute coronary syndrome male patients on dual antiplatelet therapy. <i>Thrombosis Research</i> , 2015, 136, 613-619.	0.8	4
159	Cluster-Randomized Clinical Trial Examining the Impact of Platelet Function Testing on Practice. <i>Circulation: Cardiovascular Interventions</i> , 2015, 8, e001712.	1.4	16
160	Clopidogrel response variability is associated with endothelial dysfunction in coronary artery disease patients receiving dual antiplatelet therapy. <i>Atherosclerosis</i> , 2015, 242, 102-108.	0.4	20
161	Predictive Value of High Residual Platelet Reactivity by Flow Cytometry for Outcomes of Ischemic Stroke Patients on Clopidogrel Therapy. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2015, 24, 1145-1152.	0.7	10
162	Circulating reticulated platelets over time in patients with myocardial infarction treated with prasugrel or ticagrelor. <i>Journal of Thrombosis and Thrombolysis</i> , 2015, 40, 70-75.	1.0	25
163	Mean Platelet Volume on Admission Improves Risk Prediction in Patients With Acute Coronary Syndromes. <i>Angiology</i> , 2015, 66, 456-463.	0.8	16
164	Selection of P2Y12 antagonist, treatment initiation, and predictors of high on-treatment platelet reactivity in a â€œReal Worldâ€•registry. <i>Thrombosis Research</i> , 2015, 135, 1093-1099.	0.8	15

#	ARTICLE	IF	CITATIONS
165	Pharmacodynamic effects during the transition between cangrelor and prasugrel. <i>Coronary Artery Disease</i> , 2015, 26, 42-48.	0.3	60
166	Pharmacology of antithrombotic drugs: an assessment of oral antiplatelet and anticoagulant treatments. <i>Lancet, The</i> , 2015, 386, 281-291.	6.3	209
167	Prasugrel in Clopidogrel Nonresponders Undergoing Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2015, 8, 1563-1570.	1.1	23
168	Fixed and Modifiable Correlates of Drug-Eluting Stent Thrombosis From a Large All-Comers Registry. <i>Circulation: Cardiovascular Interventions</i> , 2015, 8, .	1.4	13
169	Proton Pump Inhibitors, Platelet Reactivity, and Cardiovascular Outcomes After Drug-Eluting Stents in Clopidogrel-Treated Patients. <i>Circulation: Cardiovascular Interventions</i> , 2015, 8, .	1.4	46
170	Greater Collagen-Induced Platelet Aggregation Following Cyclooxygenase 1 Inhibition Predicts Incident Acute Coronary Syndromes. <i>Clinical and Translational Science</i> , 2015, 8, 17-22.	1.5	13
171	Antiplatelet therapy in acute coronary syndromes. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 2133-2147.	0.9	30
172	Comparison of the effect of CYP2C19 polymorphism on clinical outcome between acute coronary syndrome and stable angina. <i>Journal of Cardiology</i> , 2015, 65, 494-500.	0.8	16
173	Clopidogrel: A multifaceted affair. <i>Journal of Clinical Pharmacology</i> , 2015, 55, 1-9.	1.0	7
174	Dyspnoea management in acute coronary syndrome patients treated with ticagrelor. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2015, 4, 555-560.	0.4	45
175	Comparison of platelet inhibition by prasugrel versus ticagrelor over time in patients with acute myocardial infarction. <i>Journal of Thrombosis and Thrombolysis</i> , 2015, 39, 1-7.	1.0	25
176	Point-of-care genetic profiling and/or platelet function testing in acute coronary syndrome. <i>Thrombosis and Haemostasis</i> , 2016, 115, 382-391.	1.8	14
177	The clinical outcomes of triple antiplatelet therapy versus dual antiplatelet therapy for high-risk patients after coronary stent implantation: a meta-analysis of 11 clinical trials and 9,553 patients. <i>Drug Design, Development and Therapy</i> , 2016, Volume 10, 3435-3448.	2.0	14
178	Perioperative management of patient with intracoronary stent presenting for noncardiac surgery. <i>Annals of Cardiac Anaesthesia</i> , 2016, 19, 122.	0.3	9
179	Triple troubles selecting optimal therapy for atrial fibrillation patients undergoing percutaneous coronary interventions. <i>Postępy W Kardiologii Interwencyjnej</i> , 2016, 4, 287-289.	0.1	0
180	Ticagrelor. <i>Blood Coagulation and Fibrinolysis</i> , 2016, 27, 117-120.	0.5	13
181	Clinical significance of residual platelet reactivity in patients treated with platelet P2Y12 inhibitors. <i>Vascular Pharmacology</i> , 2016, 84, 25-27.	1.0	18
182	Safety and efficacy of policosanol in patients with high on-treatment platelet reactivity after drug-eluting stent implantation: two-year follow-up results. <i>Cardiovascular Therapeutics</i> , 2016, 34, 337-342.	1.1	11

#	ARTICLE	IF	CITATIONS
183	Bleeding events and maintenance dose of prasugrel: BLESS pilot study. <i>Open Heart</i> , 2016, 3, e000460.	0.9	8
184	Pharmacodynamic evaluation of clopidogrel reloading vs. switching to prasugrel or ticagrelor in clopidogrel resistant Indian patients. <i>Clinical Trials and Regulatory Science in Cardiology</i> , 2016, 13, 14-20.	1.0	0
185	Platelet function testing after acute myocardial infarction: The correlation among various assays is insufficient. <i>Cor Et Vasa</i> , 2016, 58, e411-e418.	0.1	0
186	Immediate response to prasugrel loading in patients with ST-elevation myocardial infarction: Predictors and outcome. <i>Thrombosis Research</i> , 2016, 144, 176-181.	0.8	2
187	Relative effects of different non-vitamin K antagonist oral anticoagulants on global thrombotic status in atrial fibrillation. <i>Platelets</i> , 2016, 27, 687-693.	1.1	16
188	Predictive performance of adding platelet reactivity on top of CRUSADE score for 1-year bleeding risk in patients with acute coronary syndrome. <i>Journal of Thrombosis and Thrombolysis</i> , 2016, 42, 360-368.	1.0	10
189	Effect of Modifying Antiplatelet Treatment to Ticagrelor in High-Risk Coronary Patients With Low Response to Clopidogrel (MATTIS). <i>Canadian Journal of Cardiology</i> , 2016, 32, 1246.e13-1246.e19.	0.8	4
190	Antithrombotic Approaches in Acute Coronary Syndromes: Optimizing Benefit vs Bleeding Risks. <i>Mayo Clinic Proceedings</i> , 2016, 91, 1413-1447.	1.4	10
191	Validation of Three Platelet Function Tests for Bleeding Risk Stratification During Dual Antiplatelet Therapy Following Coronary Interventions. <i>Clinical Cardiology</i> , 2016, 39, 385-390.	0.7	13
192	Intensive atorvastatin improves endothelial function and decreases ADP-induced platelet aggregation in patients with STEMI undergoing primary PCI: A single-center randomized controlled trial. <i>International Journal of Cardiology</i> , 2016, 222, 467-472.	0.8	12
193	Morphine use and myocardial reperfusion in patients with acute myocardial infarction treated with primary PCI. <i>International Journal of Cardiology</i> , 2016, 221, 567-571.	0.8	41
194	Relationship of paraoxonase-1 Q192R genotypes and in-stent restenosis and re-stenting in Chinese patients after coronary stenting. <i>Atherosclerosis</i> , 2016, 251, 305-310.	0.4	10
195	Improved predictive value of GRACE risk score combined with platelet reactivity for 1-year cardiovascular risk in patients with acute coronary syndrome who underwent coronary stent implantation. <i>Platelets</i> , 2016, 27, 650-657.	1.1	7
196	Platelet function testing as a biomarker for efficacy of antiplatelet drugs. <i>Biomarkers in Medicine</i> , 2016, 10, 903-918.	0.6	8
197	Hyper-Response to Clopidogrel in Japanese Patients Undergoing Transcatheter Aortic Valve Implantation. <i>International Heart Journal</i> , 2016, 57, 190-197.	0.5	19
198	Platelet aggregation and risk of stent thrombosis or bleeding in interventional treated diabetic patients with acute coronary syndrome. <i>BMC Cardiovascular Disorders</i> , 2016, 16, 252.	0.7	9
199	Association of VEGFR-2 Gene Polymorphisms With Clopidogrel Resistance in Patients With Coronary Heart Disease. <i>American Journal of Therapeutics</i> , 2016, 23, e1663-e1670.	0.5	9
200	The Importance of the Mean Platelet Aggregation Degree in Long-term Dual Antiplatelet Therapy Following Drug-eluting Stent Implantation. <i>Cardiovascular Therapeutics</i> , 2016, 34, 127-137.	1.1	1

#	ARTICLE	IF	CITATIONS
201	Factors influencing platelet reactivity in patients undergoing coronary artery bypass surgery. <i>Coronary Artery Disease</i> , 2016, 27, 185-190.	0.3	3
202	Platelets and Inflammatory Parameters Do Not Affect Long-Term Survival after Acute Stroke. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2016, 25, 1936-1938.	0.7	0
203	The challenge for predicting bleeding events by assessing platelet reactivity following coronary stenting. <i>International Journal of Cardiology</i> , 2016, 207, 128-131.	0.8	7
204	High on-aspirin platelet reactivity predicts cardiac death in acute coronary syndrome patients undergoing PCI. <i>European Journal of Internal Medicine</i> , 2016, 30, 49-54.	1.0	17
205	High residual platelet reactivity (HRPR) for adenosine diphosphate (ADP) stimuli is a determinant factor for long-term outcomes in acute ischemic stroke with anti-platelet agents: The meaning of HRPR after ADP might be more prominent in large atherosclerotic infarction than other subtypes of AIS. <i>Journal of Thrombosis and Thrombolysis</i> , 2016, 42, 107-117.	1.0	7
206	P2Y ₁₂ receptor blockade synergizes strongly with nitric oxide and prostacyclin to inhibit platelet activation. <i>British Journal of Clinical Pharmacology</i> , 2016, 81, 621-633.	1.1	27
207	Clinical Significance of Laboratory-determined Aspirin Poor Responsiveness After Primary Percutaneous Coronary Intervention. <i>Cardiovascular Drugs and Therapy</i> , 2016, 30, 151-158.	1.3	4
208	Reply. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 106-107.	1.1	0
209	The use of platelet reactivity testing in patients on antiplatelet therapy for prediction of bleeding events after cardiac surgery. <i>Vascular Pharmacology</i> , 2016, 77, 19-27.	1.0	15
210	Comparison of VerifyNow P2Y ₁₂ and thrombelastography for assessing clopidogrel response in stroke patients in China. <i>Neurological Sciences</i> , 2016, 37, 277-282.	0.9	18
211	On-treatment platelet reactivity: State of the art and perspectives. <i>Vascular Pharmacology</i> , 2016, 77, 8-18.	1.0	19
212	2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. <i>European Heart Journal</i> , 2016, 37, 267-315.	1.0	5,890
213	Personalized ADP-receptor inhibition strategy and outcomes following primary PCI for STEMI (PASTOR) Tj ETQq0 0 0 rgBT /Overlock 10 T	0.8	4
214	Traditional clinical risk factors predict clopidogrel hypo-responsiveness in unselected patients undergoing non-emergent percutaneous coronary intervention. <i>Platelets</i> , 2016, 27, 51-58.	1.1	2
215	The Impact of CYP2C19 Loss-of-Function Polymorphisms, Clinical, and Demographic Variables on Platelet Response to Clopidogrel Evaluated Using Impedance Aggregometry. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2017, 23, 255-265.	0.7	16
216	Clinical significance of platelet reactivity during prasugrel therapy in patients with acute myocardial infarction. <i>Journal of Cardiology</i> , 2017, 70, 35-40.	0.8	4
217	Platelet reactivity in human immunodeficiency virus-infected patients on dual antiplatelet therapy for an acute coronary syndrome: the EVERE ₂ -ST-HIV study. <i>European Heart Journal</i> , 2017, 38, ehw583.	1.0	25
218	Conundrums of Platelet Function Testing. <i>Circulation: Cardiovascular Interventions</i> , 2017, 10, .	1.4	0

#	ARTICLE	IF	CITATIONS
220	Optimal Same-Day Platelet Inhibition in Patients Receiving Drug-Eluting Stents With or Without Previous Maintenance Thienopyridine Therapy : from the Evaluation of Platelet Inhibition in Patients Having A VerifyNow Assay (EPIPHANY) Trial. American Journal of Cardiology, 2017, 119, 991-995.	0.7	4
221	Current Role of Platelet Function Testing in Percutaneous Coronary Intervention and Coronary Artery Bypass Grafting. Interventional Cardiology Clinics, 2017, 6, 151-166.	0.2	4
222	Individualized dual antiplatelet therapy based on platelet function testing in patients undergoing percutaneous coronary intervention: a meta-analysis of randomized controlled trials. BMC Cardiovascular Disorders, 2017, 17, 157.	0.7	17
223	Impact of mean platelet aggregation degree on long-term clinical outcomes among patients undergoing a complex percutaneous coronary intervention. Coronary Artery Disease, 2017, 28, 478-485.	0.3	3
224	Association of measured platelet reactivity with changes in P2Y ₁₂ receptor inhibitor therapy and outcomes after myocardial infarction: Insights into routine clinical practice from the Treatment with ADP receptor iNhibitorS: Longitudinal Assessment of Treatment Patterns and Events after Acute Coronary Syndrome (TRANSLATE-ACS) study. American Heart Journal, 2017, 187, 19-28.	1.2	14
225	The long way to better PCI results in diabetic patients. International Journal of Cardiology, 2017, 245, 90-91.	0.8	0
226	CRUSADE Score is Superior to Platelet Function Testing for Prediction of Bleeding in Patients Following Coronary Interventions. EBioMedicine, 2017, 21, 213-217.	2.7	3
227	Platelet oxidative stress as a novel target of cardiovascular risk in frail older people. Vascular Pharmacology, 2017, 93-95, 14-19.	1.0	25
228	Impact of Aspirin and Clopidogrel Hyporesponsiveness in Patients Treated With Drug-Eluting Stents. JACC: Cardiovascular Interventions, 2017, 10, 1607-1617.	1.1	29
229	P2Y ₁₂ receptor inhibitor resistance and coronary artery disease. Current Opinion in Cardiology, 2017, 32, 617-626.	0.8	1
230	Long-term versus short-term dual antiplatelet therapy was similarly associated with a lower risk of death, stroke, or infarction in patients with acute coronary syndrome regardless of underlying kidney disease. Kidney International, 2017, 91, 216-226.	2.6	16
231	Antithrombotic potency of ticagrelor versus clopidogrel in type-2 diabetic patients with cardiovascular disease. Thrombosis and Haemostasis, 2017, 117, 1981-1988.	1.8	15
232	Benefit of Switching Dual Antiplatelet Therapy After Acute Coronary Syndrome According to On-Treatment Platelet Reactivity. JACC: Cardiovascular Interventions, 2017, 10, 2560-2570.	1.1	36
233	Stable Ischemic Heart Disease. , 2018, , 591-630.		2
234	Systemic inflammatory status is associated with increased platelet reactivity in the early period after acute coronary syndromes. Platelets, 2018, 29, 528-530.	1.1	8
235	Body Mass Index and Plasma P-Selectin before Coronary Stenting Predict High Residual Platelet Reactivity at 6 Months on Dual Antiplatelet Therapy. Cardiology, 2018, 139, 132-136.	0.6	8
236	Antithrombotic and Antiplatelet Therapy. , 2018, , 53-59.		0
237	Impact of hepatitis B virus (HBV) infection on platelet response to clopidogrel in patients undergoing coronary stent implantation. Thrombosis Research, 2018, 167, 119-124.	0.8	4

#	ARTICLE	IF	CITATIONS
238	Optimal treatment of patients with NSTEMI-ACS in the Dutch health care system. <i>Netherlands Heart Journal</i> , 2018, 26, 289-295.	0.3	1
239	Temporal Changes in Platelet Response in Acute Coronary Syndrome Patients With Prasugrel and Clopidogrel After Stent Implantation. <i>Circulation Journal</i> , 2018, 82, 353-360.	0.7	5
240	Optimal platelet function test for in-stent tissue protrusion following carotid artery stenting. <i>Journal of International Medical Research</i> , 2018, 46, 1866-1875.	0.4	2
241	Aggregometry in the settings of thrombocytopenia, thrombocytosis and antiplatelet therapy. <i>Platelets</i> , 2018, 29, 644-649.	1.1	9
242	First 24h in the management of non-ST segment elevation myocardial infarction. <i>European Heart Journal Supplements</i> , 2018, 20, B29-B38.	0.0	1
243	Relationship between CHA ₂ DS ₂ -VASc score, coronary artery disease severity, residual platelet reactivity and long-term clinical outcomes in patients with acute coronary syndrome. <i>International Journal of Cardiology</i> , 2018, 262, 9-13.	0.8	18
244	On-treatment platelet reactivity in peripheral and coronary blood in patients undergoing primary PCI for ST-segment elevation myocardial infarction (STEMI). <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2018, 78, 281-286.	0.6	1
245	Optimal antiplatelet therapy after an acute coronary syndrome in the elderly: An old issue. <i>International Journal of Cardiology</i> , 2018, 259, 49-50.	0.8	0
246	Impact of CYP2C19 Polymorphisms on Clinical Outcomes and Antiplatelet Potency of Clopidogrel in Caucasian Poststroke Survivors. <i>American Journal of Therapeutics</i> , 2018, 25, e202-e212.	0.5	12
247	Adenosine A _{2A} receptor agonists with potent antiplatelet activity. <i>Platelets</i> , 2018, 29, 292-300.	1.1	20
248	Platelet reactivity-adjusted antiplatelet therapy in patients with percutaneous coronary intervention: a meta-analysis of randomized controlled trials. <i>Platelets</i> , 2018, 29, 589-595.	1.1	3
249	A cost-effectiveness and safety analysis of dual antiplatelet therapy comparing aspirin+clopidogrel to aspirin+ticagrelor in patients with acute coronary syndrome. <i>Medical Journal of Indonesia</i> , 2018, 27, 262-70.	0.2	2
250	Monitoring platelet function: what have we learned from randomized clinical trials?. <i>Cardiovascular Diagnosis and Therapy</i> , 2018, 8, 621-629.	0.7	5
251	Impact of Obstructive Sleep Apnea on Platelet Function Profiles in Patients With Acute Coronary Syndrome Taking Dual Antiplatelet Therapy. <i>Journal of the American Heart Association</i> , 2018, 7, e008808.	1.6	9
252	The Evolving Concept of Dual Antiplatelet Therapy after Percutaneous Coronary Intervention: Focus on Unique Feature of East Asian and Asian Paradox. <i>Korean Circulation Journal</i> , 2018, 48, 537.	0.7	52
253	Acute Coronary Syndrome. , 2018, , 147-161.		2
254	Effects of genetic variation in protease activated receptor 4 after an acute coronary syndrome: Analysis from the TRACER trial. <i>Blood Cells, Molecules, and Diseases</i> , 2018, 72, 37-43.	0.6	10
255	On-Treatment Platelet Reactivity is a Predictor of Adverse Events in Peripheral Artery Disease Patients Undergoing Percutaneous Angioplasty. <i>European Journal of Vascular and Endovascular Surgery</i> , 2018, 56, 545-552.	0.8	10

#	ARTICLE	IF	CITATIONS
256	Potent effect of prasugrel on acute phase resolution of intra-stent athero-thrombotic burden after percutaneous intervention to acute coronary syndrome. <i>Journal of Cardiology</i> , 2018, 72, 403-410.	0.8	1
257	Peri-Procedural Platelet Reactivity in Percutaneous Coronary Intervention. <i>Thrombosis and Haemostasis</i> , 2018, 118, 1131-1140.	1.8	11
259	The Role of Novel Oral Anticoagulants and Antiplatelet Therapy after Percutaneous Coronary Intervention: Individualizing Therapy to Optimize Outcomes. <i>Korean Circulation Journal</i> , 2019, 49, 645.	0.7	3
260	Antagonizing P2Y12 Receptor Inhibitors: Current and Future Options. <i>Thrombosis and Haemostasis</i> , 2019, 119, 1606-1616.	1.8	11
261	Relationship of Platelet Reactivity and Inflammatory Markers to Recurrent Adverse Events in Patients with ST-Elevation Myocardial Infarction. <i>Thrombosis and Haemostasis</i> , 2019, 119, 1785-1794.	1.8	11
262	Non-ST Elevation Myocardial Infarction: Diagnosis and Management. , 0, , .		3
263	Vascular response to paclitaxel-eluting nitinol self-expanding stent in superficial femoral artery lesions: post-implantation angioscopic findings from the SHIMEJI trial (Suppression of vascular wall) <i>Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5</i>	0.7	4
264	1777-1784. A brief review on resistance to P2Y12 receptor antagonism in coronary artery disease. <i>Thrombosis Journal</i> , 2019, 17, 11.	0.9	46
265	Half-dose ticagrelor versus high-dose clopidogrel in reducing platelet reactivity in acute coronary syndrome patients with high on-clopidogrel platelet reactivity (divide study). <i>European Journal of Clinical Pharmacology</i> , 2019, 75, 1059-1068.	0.8	11
266	Pharmacodynamic changes of platelet reactivity status in patients with chronic kidney disease after coronary artery stenting. <i>Biomedicine and Pharmacotherapy</i> , 2019, 113, 108773.	2.5	3
267	Platelet Function Testing in Clinical Research Trials. , 2019, , 683-700.		0
268	<p>Comparisons between ticagrelor and clopidogrel following percutaneous coronary intervention in patients with acute coronary syndrome: a comprehensive meta-analysis<p>. <i>Drug Design, Development and Therapy</i> , 2019, Volume 13, 719-730.	2.0	21
269	P2Y12 Antagonists. , 2019, , 937-956.		1
270	High on-clopidogrel platelet reactivity and chronic kidney disease: a meta-analysis of literature studies. <i>Scandinavian Cardiovascular Journal</i> , 2019, 53, 55-61.	0.4	9
271	Platelet Surface CD62p and Serum Vitamin D Levels are Associated with Clopidogrel Resistance in Chinese Patients with Ischemic Stroke. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2019, 28, 1323-1328.	0.7	13
272	Adverse events in patients with high platelet reactivity following successful chronic total occlusion PCI: The Assessment of Dual AntiPlatelet Therapy with Drug-Eluting Stents (ADAPT-DES) study. <i>American Heart Journal</i> , 2019, 211, 68-76.	1.2	3
273	Effects of Crushed Ticagrelor Versus Eptifibatide Bolus Plus Clopidogrel in Troponinâ€Negative Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention: A Randomized Clinical Trial. <i>Journal of the American Heart Association</i> , 2019, 8, e012844.	1.6	11
274	Association between changes in platelet reactivity during elective percutaneous coronary intervention and periprocedural myocardial infarction: A pilot study. <i>Journal of Cardiology</i> , 2019, 73, 134-141.	0.8	1

#	ARTICLE	IF	CITATIONS
275	Predictors of strut coverage of drug eluting stent implantation in diabetic patients. <i>International Journal of Cardiology</i> , 2019, 276, 61-65.	0.8	3
276	Adjunctive Pharmacologic Therapies in Acute Myocardial Infarction. , 2019, , 117-138.e7.		2
277	Discontinuation of dual antiplatelet therapy and bleeding in intensive care in patients undergoing urgent coronary artery bypass grafting: a retrospective analysis. <i>Interactive Cardiovascular and Thoracic Surgery</i> , 2019, 28, 665-673.	0.5	11
278	Pre-hospital administration of ticagrelor in diabetic patients with ST-elevation myocardial infarction undergoing primary angioplasty: A sub-analysis of the ATLANTIC trial. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 93, E369-E377.	0.7	4
279	Direct factor IXa inhibition with the RNA-aptamer pegnivacogin reduces platelet reactivity in vitro and residual platelet aggregation in patients with acute coronary syndromes. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2019, 8, 520-526.	0.4	14
280	Homocysteine levels and platelet reactivity in coronary artery disease patients treated with ticagrelor. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2020, 30, 292-299.	1.1	12
281	Prognostic relevance of GRACE risk score in Takotsubo syndrome. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2020, 9, 721-728.	0.4	16
282	Impact of high on-treatment platelet reactivity on outcomes following PCI in patients on hemodialysis: An ADAPTES substudy. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 96, 793-801.	0.7	6
283	The impact of cytochrome 450 and Paraoxonase polymorphisms on clopidogrel resistance and major adverse cardiac events in coronary heart disease patients after percutaneous coronary intervention. <i>BMC Pharmacology & Toxicology</i> , 2020, 21, 1.	1.0	26
284	Prognostic significance of reticulated platelet levels in diabetic patients with stable coronary artery disease. <i>Platelets</i> , 2020, 31, 1012-1018.	1.1	13
285	Diurnal variations in tissue factor and tissue factor pathway inhibitor concentrations in relation to on-treatment platelet reactivity: an analysis of patients with acute myocardial infarction. <i>Platelets</i> , 2020, 31, 877-883.	1.1	3
286	Platelet Function in Cardiovascular Disease: Activation of Molecules and Activation by Molecules. <i>Cardiovascular Toxicology</i> , 2020, 20, 1-10.	1.1	70
287	Low Response to Clopidogrel in Coronary Artery Disease. <i>American Journal of Therapeutics</i> , 2020, 27, e133-e141.	0.5	9
288	Serum uric acid level negatively correlated with the prevalence of clopidogrel low response in patients undergoing antiplatelet treatment with aspirin and clopidogrel. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2020, 30, 2215-2220.	1.1	2
289	Platelet Inhibition with Ticagrelor versus Clopidogrel in Diabetic Patients after Percutaneous Coronary Intervention for Chronic Coronary Syndromes. <i>Thrombosis and Haemostasis</i> , 2020, 120, 1221-1229.	1.8	8
290	Antithrombotic therapy in acute coronary syndrome: undertreatment of elderly?. <i>Monaldi Archives for Chest Disease</i> , 2020, 90, .	0.3	0
291	Platelet Reactivity in Hepatitis C Virus-Infected Patients on Dual Antiplatelet Therapy for Acute Coronary Syndrome. <i>Journal of the American Heart Association</i> , 2020, 9, e016441.	1.6	7
292	Cyp2C19*2 Polymorphism Related to Clopidogrel Resistance in Patients With Coronary Heart Disease, Especially in the Asian Population: A Systematic Review and Meta-Analysis. <i>Frontiers in Genetics</i> , 2020, 11, 576046.	1.1	12

#	ARTICLE	IF	CITATIONS
293	Dual antiplatelet therapy in patients with acute coronary syndrome during the coronavirus disease of 2019 pandemic: the right choice at the right time. <i>Journal of Cardiovascular Medicine</i> , 2020, 21, 535-537.	0.6	8
294	Clinical Implications of Tailored Antiplatelet Therapy in Patients With Chronic Total Occlusion. <i>Journal of the American Heart Association</i> , 2020, 9, e014676.	1.6	9
295	Patient and hospital characteristics associated with ticagrelor uptake in acute MI: An analysis of the Chest Pain–MI Registry. <i>International Journal of Cardiology</i> , 2020, 304, 14-20.	0.8	4
296	Genetic polymorphisms of high platelet reactivity in Chinese patients with coronary heart disease under clopidogrel therapy. <i>International Journal of Clinical Pharmacy</i> , 2020, 42, 158-166.	1.0	4
297	Résistance aux antiplaquettaires : mythe ou réalité ? . <i>Revue Francophone Des Laboratoires</i> , 2020, 2020, 59-64.	0.0	0
298	Aspirin adherence in subjects with glucose-6-phosphate-dehydrogenase deficiency having an acute coronary syndrome. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, e41-w44.	1.4	4
299	Point-of-Care Platelet Function Monitoring: Implications for Patients With Platelet Inhibitors in Cardiac Surgery. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2021, 35, 1049-1059.	0.6	25
300	Efficacy and Safety of Ticagrelor vs. Clopidogrel in East Asian Patients with Acute Myocardial Infarction: A Nationwide Cohort Study. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 443-451.	2.3	6
301	Acute coronary syndromes and percutaneous coronary intervention—current recommendations for dual antiplatelet therapy. Are guidelines reflecting the data? ., 2021, , 57-77.		0
302	Stent Thrombosis Risk Over Time on the Basis of Clinical Presentation and Platelet Reactivity. <i>JACC: Cardiovascular Interventions</i> , 2021, 14, 417-427.	1.1	19
303	Independent predictors of acute kidney injury in patients with acute coronary syndrome after percutaneous coronary intervention. <i>PLoS ONE</i> , 2021, 16, e0247304.	1.1	4
304	Leuko-platelet index predicts thrombotic events in patients with acute coronary syndrome. <i>International Journal of Cardiology</i> , 2021, 328, 29-34.	0.8	0
305	Not-high before-treatment platelet reactivity in patients with STEMI: prevalence, clinical characteristics, response to therapy and outcomes. <i>Platelets</i> , 2022, 33, 390-397.	1.1	3
306	Performance comparison of aspirin assay between ansys and verifynow: Assessment of therapeutic platelet inhibition in patients with cardiac diseases. <i>Clinical Hemorheology and Microcirculation</i> , 2021, 79, 1-8.	0.9	1
307	Inflammation during Percutaneous Coronary Intervention—Prognostic Value, Mechanisms and Therapeutic Targets. <i>Cells</i> , 2021, 10, 1391.	1.8	16
308	MiR-223 or miR-126 predicts resistance to dual antiplatelet therapy in patients with ST-elevation myocardial infarction. <i>Journal of International Medical Research</i> , 2021, 49, 0300060521110162.	0.4	5
309	Evolution of antithrombotic therapy in patients undergoing percutaneous coronary intervention: a 40-year journey. <i>European Heart Journal</i> , 2021, 42, 339-351.	1.0	57
310	Association of CYP2C19 Polymorphism with Clopidogrel Resistance in Patients with Acute Coronary Syndrome in China. <i>Medical Science Monitor</i> , 2019, 25, 7138-7148.	0.5	13

#	ARTICLE	IF	CITATIONS
312	Combined Antiplatelet Therapy: Still a Sweeping Combination in Cardiology. <i>Cardiovascular and Hematological Agents in Medicinal Chemistry</i> , 2013, 11, 136-167.	0.4	6
313	Very late stent thrombosis of bare-metal coronary stent nine years after primary percutaneous coronary intervention. <i>Vojnosanitetski Pregled</i> , 2016, 73, 774-778.	0.1	1
314	A pharmacodynamic study of the optimal P2Y ₁₂ inhibitor regimen for East Asian patients with acute coronary syndrome. <i>Korean Journal of Internal Medicine</i> , 2015, 30, 620-628.	0.7	21
315	Clopidogrel Resistance. <i>Korean Journal of Medicine</i> , 2013, 85, 1.	0.1	2
316	High residual platelet reactivity on clopidogrel: its significance and therapeutic challenges overcoming clopidogrel resistance. <i>Cardiovascular Diagnosis and Therapy</i> , 2013, 3, 23-37.	0.7	25
317	Stent-related defects in patients presenting with stent thrombosis: differences at optical coherence tomography between subacute and late/very late thrombosis in the Mechanism Of Stent Thrombosis (MOST) study. <i>EuroIntervention</i> , 2013, 9, 936-944.	1.4	53
318	2014 ESC/EACTS Guidelines on myocardial revascularization. <i>EuroIntervention</i> , 2015, 10, 1024-1094.	1.4	251
320	The Role of Laboratory Monitoring in Antiplatelet Therapy. <i>Handbook of Experimental Pharmacology</i> , 2012, , 471-494.	0.9	2
321	Clinical significance of monitoring tests for anti-platelet drugs. <i>Japanese Journal of Thrombosis and Hemostasis</i> , 2012, 23, 352-357.	0.1	1
323	Cilostazol Added to Dual Antiplatelet Therapy for Patients with High Risk of Restenosis after Drug-Eluting Stent Implantation: A Systematic Review and Meta-Analysis of RCTs. <i>Cardiovascular Pharmacology: Open Access</i> , 2015, 04, .	0.1	1
324	Outline of Recommendations for the standardization of light transmission aggregometry: a consensus of the working party from the platelet physiology subcommittee of SSC/ISTH. <i>Japanese Journal of Thrombosis and Hemostasis</i> , 2016, 27, 365-369.	0.1	2
325	Inhibidores del receptor plaquetario P2Y ₁₂ . Parte 2 de 2: etiología, diagnóstico y manejo de la resistencia. <i>Medicina Y Laboratorio</i> , 2017, 23, 313-348.	0.0	1
328	(In what extent we reached the standards of antiplatelet therapy in secondary prevention of) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 262	0.1	0
329	Genetic Polymorphisms Association in Restenosis of Coronary Arteries. <i>Open Access Macedonian Journal of Medical Sciences</i> , 2020, 8, 666-672.	0.1	0
330	Monitoring and tailoring the P2Y ₁₂ ADP receptor blocker therapy. <i>Vnitni Lekarstvi</i> , 2020, 66, e26-e33.	0.1	0
331	Relationship between ADP-induced platelet-fibrin clot strength and anti-platelet responsiveness in ticagrelor treated ACS patients. <i>Journal of Geriatric Cardiology</i> , 2016, 13, 282-9.	0.2	2
332	Identification of key gene modules and pathways of human platelet transcriptome in acute myocardial infarction patients through co-expression network. <i>American Journal of Translational Research (discontinued)</i> , 2021, 13, 3890-3905.	0.0	1
333	Comparison of Clinical Outcomes Between Ticagrelor and Clopidogrel in Acute Coronary Syndrome: A Comprehensive Meta-Analysis. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 818215.	1.1	9

#	ARTICLE	IF	CITATIONS
334	Dual Antiplatelet Therapy with 3rd Generation P2Y12 Inhibitors in STEMI Patients: Impact of Body Mass Index on Loading Doseâ€“Response. <i>Cardiovascular Drugs and Therapy</i> , 2023, 37, 695-703.	1.3	7
335	Antiplatelet therapy after percutaneous coronary intervention. <i>EuroIntervention</i> , 2022, 17, e1371-e1396.	1.4	94
336	Antiplatelet response to clopidogrel is associated with a haplotype in CYP2C19 gene in Pakistani patients. <i>Scientific Reports</i> , 2022, 12, 6171.	1.6	2
337	Outcomes of Left Main Revascularization after Percutaneous Intervention or Bypass Surgery. <i>Journal of Interventional Cardiology</i> , 2022, 2022, 1-9.	0.5	4
342	Association of Î±2A-Adrenergic Receptor Genetic Variants with Platelet Reactivity in Chinese Patients on Dual Antiplatelet Therapy Undergoing Percutaneous Coronary Intervention. <i>Biomedical and Environmental Sciences</i> , 2017, 30, 898-906.	0.2	1
344	An Insight into Recent Advances on Platelet Function in Health and Disease. <i>International Journal of Molecular Sciences</i> , 2022, 23, 6022.	1.8	15
345	Evaluation of Drugs and Strategies for Treating Coronary Artery Ectasia: Update and Future Perspective. <i>Jundishapur Journal of Chronic Disease Care</i> , 2022, In Press, .	0.1	1
346	Infarct Size and Long-Term Clinical Outcomes of Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndrome Undergoing Coronary Artery Stenting: A Prospective Randomized Study. <i>International Journal of Angiology</i> , 2023, 32, 056-065.	0.2	1
347	Effect of cocoa (<i>Theobroma cacao</i> L.) on platelet function testing profiles in patients with coronary artery disease: ECLAIR pilot study. <i>Open Heart</i> , 2022, 9, e002066.	0.9	2
348	Elevated serum C1q is an independent predictor of high residual platelet reactivity in CAD patients receiving clopidogrel therapy. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	0
349	Efficacy and safety of dual antiplatelet therapy after percutaneous coronary drug-eluting stenting: A network meta-analysis. <i>Medicine (United States)</i> , 2022, 101, e31158.	0.4	1
350	Approaches to de-escalation of antiplatelet treatment in stabilized post-myocardial infarction patients with high ischemic risk. <i>Expert Review of Cardiovascular Therapy</i> , 2022, 20, 839-849.	0.6	2
351	The impact of high on-treatment platelet reactivity and fibrinogen levels on ischemic events in patients with ST elevation myocardial infarction: a prospective observational study. <i>International Journal of Clinical Pharmacy</i> , 2023, 45, 461-472.	1.0	1
352	Genotyping genetic variants of <i>CYP2C19</i> for precision antiplatelet dosing: state of the art and future perspectives. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2022, 18, 817-830.	1.5	1
353	High-on-treatment platelet reactivity predicts adverse outcome after carotid artery stenting: A prospective study. <i>Thrombosis Research</i> , 2023, 222, 117-123.	0.8	1
354	Clinical outcomes of individualized antiplatelet therapy based on platelet function test in patients after percutaneous coronary intervention: a systematic review and meta-analysis. <i>Journal of Cardiovascular Pharmacology</i> , 2022, Publish Ahead of Print, .	0.8	1
355	Clinical impact of high platelet reactivity in patients with atrial fibrillation and concomitant percutaneous coronary intervention on dual or triple antithrombotic therapy. <i>Journal of Thrombosis and Thrombolysis</i> , 2023, 55, 667-679.	1.0	2
360	High BMI: Another Barrier to Rapid Platelet Inhibition After STEMI PCI. <i>Cardiovascular Drugs and Therapy</i> , 2024, 38, 9-11.	1.3	0

#	ARTICLE	IF	CITATIONS
---	---------	----	-----------